Now Published! HBV Serum Biomarkers Article in Nature Reviews | Gastroenterology & Hepatology

We are delighted to share our HBV Serum Biomarkers manuscriptm,  recently published online at Nature Reviews Gastroenterology and Hepatology. This publication is an important review, which culminates almost 2 years work since the ICE-HBV Serum Biomarkers workshops online in 2020.

Rewatch the Workshop here



Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although thereis a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure.Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkersare available for monitoring or predicting HBV disease progression and treatment response. Asnew therapies become available, new biomarkers to monitor viral and host responses are urgentlyneeded. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) helda virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting.Various stakeholders from academia, clinical practice and the pharmaceutical industry, withcomplementary expertise, presented and participated in panel discussions. The clinical utility ofboth classic and emerging viral and immunological serum biomarkers with respect to the courseof infection, disease progression, and response to current and emerging treatments was appraised.The latest advances were discussed, and knowledge gaps in understanding and interpretationof HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses,opportunities and challenges of HBV biomarkers.

Read the full article here.

For more ICE-HBV publication, check out our Publication Page here.


Recently Published Protocols